Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority Trial

作者：Ning Kong, Yu Xue, Li Mao, Long Qian, Hongtao Guo, Jiankang Hu, Fenghong Yuan, Rongbin Li, Xinwang Duan, Jing Yu, Wei Gou, Lei Yang, Hua Wei, Ran Li, Qian Xu, Tianhong Luo, Xu Zhang, Hejian Zou · 发表于：Rheumatology and Therapy · 年份：2025 · DOI：10.1007/s40744-025-00790-6 · 被引用次数：7 · 研究领域：Gout, Hyperuricemia, Uric Acid、Rheumatoid Arthritis Research and Therapies、Medicinal plant effects and applications

INTRODUCTION: Firsekibart, an anti-interleukin (IL)-1β monoclonal antibody, has demonstrated more sustained control of gout flares compared with compound betamethasone in previous clinical studies. This study evaluated the efficacy and safety of firsekibart versus etoricoxib for the treatment of frequent gout flares. METHODS: In this phase 2, randomized, open-label, active-controlled, multicenter study (NCT05936268), adults with gout according to American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) 2015 criteria experiencing frequent flares (≥ 2 flares within 12 months pre-screening) were randomized (1:1) to receive either a single subcutaneous injection of firsekibart 200 mg, or once-daily oral etoricoxib 120 mg administered until pain remission or treatment intolerance for up to 8 days. The primary endpoint was change from baseline in target joint pain intensity (0-100 mm visual analogue scale [VAS]) 72 h post-treatment. Non-inferiority (margin: 10 mm) was assessed first; if achieved, superiority was subsequently evaluated. Safety was also evaluated. RESULTS: Overall, 123 patients received firsekibart (n = 61) or etoricoxib (n = 62). Firsekibart was non-inferior and superior to etoricoxib in change from baseline in target joint pain VAS scores at 72 h post-treatment (difference: - 10.91 mm; 95% confidence interval [CI]: - 18.11, - 3.72). Treatment-emergent adverse events (TEAEs) occurred in 77.0% (n = 47) and 51.6% (n = 32) of patients recei...